Showing results (581-590 of 2,338) with videos related to
Sort By:
Pageof 234
Clinical Lung Cancer|December 25, 2021
The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literatureChiara Catania, Bharathi Muthusamy, Gianluca Spitaleri, et al.Clinical Lung Cancer|December 26, 2021
NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohortS Heynemann, H Yu, L Churilov, et al.Clinical Lung Cancer|February 3, 2012
Beyond bevacizumab: antiangiogenic agentsShane Rogosin, Alan B SandlerClinical Lung Cancer|April 14, 2012
A diagnostic program for patients suspected of having lung cancerJos A Stigt, Steven M Uil, Ad H Oostdijk, et al.Clinical Lung Cancer|July 7, 2011
Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group studyKazuhiro Asami, Tomonobu Koizumi, Kazuya Hirai, et al.Clinical Lung Cancer|July 7, 2011
EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastasesHye-Suk Han, Dae-Woon Eom, Joo Heon Kim, et al.Clinical Lung Cancer|June 14, 2011
Clinical trials of vascular disrupting agents in advanced non--small-cell lung cancerMark J McKeageClinical Lung Cancer|June 14, 2011
Scar carcinoma of the lung: a historical perspectiveRavi K Bobba, Jason Scott Holly, Tim Loy, et al.Clinical Lung Cancer|June 14, 2011
A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancerLeora Horn, Zhiguo Zhao, Alan Sandler, et al.Clinical Lung Cancer|June 14, 2011
Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC)Susana Cedrés, Isaac Nuñez, Marina Longo, et al.Pageof 234